Histopathologic and Immunohistochemical Analysis of Neurofibromas in a North-Western Nigerian Tertiary Hospital: A Ten-Year Retrospective Study.
Main Article Content
Keywords
Neurofibroma, Females, Head & Neck, S100, CD34, Ki67, Calretinin, SOX10
Abstract
Background: Neurofibromas are the most common benign nerve sheath tumours occurring as solitary sporadic tumours or multiple Syndromic tumours associated with neurofibromatosis type 1(NF1). In Nigeria and West Africa, there is a paucity of literature and studies on neurofibromas. This study aims to analyse the histopathologic and immunohistochemical patterns of neurofibromas and also determine the frequency, demographic and anatomic distributions.
Methodology: The study was a hospital-based retrospective study and the study population constituted all surgical specimens submitted for histological examination to the Department of Pathology between 1st January 2010 to 31st December 2019 reported as neurofibroma. Records were retrieved from the archives and subjected to histopathologic and immunohistochemical analysis following standard protocols. Collated data was analysed, slides were reviewed and results were presented in frequency distribution tables and statistical charts.
Results: A total of 125 cases were seen constituting 8.3% of all soft tissue tumours seen. Neurofibromas were more prevalent in females with a male-to-female ratio of 1:1.15. The age ranged between 2-70 years with a mean age of 25.38 years and the highest frequency of occurrence was in the second decade of life. The most frequent anatomic site of occurrence was the head and neck region. Most of the tumours 103 (82.4%) were sporadic while 22(17.6%) were Syndromic and associated with NF1. A malignant transformation of a pre-existing neurofibroma in an NF1 patient was seen. The most common histologic variant seen was the conventional variant. Ninety percent of these tumours showed SOX10 immunopositivity, 91% showed S100 immunopositivity and 95% showed CD34 immunopositivity. Calretinin expression was low showing 16%. No hot spots labeling index seen with Ki67 antibody.
Conclusion: Neurofibromas are more common in females in our environment and the most frequent anatomic site of involvement is the head and neck region.
References
2. Le LQ, Liu C, Shipman T, Chen Z, Suter U, Parada LF. Susceptible stages in Schwann cells for NF-1 associated plexiform neurofibroma development. Can Res 2011; 71(13):4686-4695. doi:10.1158/0008-5472.CAN-10-4577.
3. Thway K, Fisher C. Malignant peripheral nerve sheath tumour: pathology and genetics. Ann Diagn Pathol 2014 18(2):109-116. doi:10.1016/j.anndiagpath.2013. 10.007.
4. Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumours: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 2012; 123(03):295-319. doi: 10.1007/s00401-012-0954-z.
5. Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling, et al. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumour and cellular schwannomas. Mod Pathol 2015; 28(2):187-200. doi: 10.1038/modpathol.2014.109.
6. do Nascimento GJ, de Albuquerque Pires Rocha D, Galvão HC, de Lisboa Lopes Costa A, de Souza LB. A 38-year review of oral schwannomas and neurofibromas in a Brazilian population: Clinical, histopathological and immunohistochemical study. Clin Oral Investig 2011; 15(3):329-335. doi: 10. 1007/s00784-010-0389-7.
7. Antonescu CR, Brems H, Legius E, Woordruff JM. Nerve sheath tumours. In: Fletcher CDM, Julia AB, Hogendoorn CW, Fredrik M (Eds). World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC press; 2013:p170-191.
8. Francisco A, Forte Oliveria, Clarissa F, Mário R, Mário RL, Fabrício. Expression of S100, EMA.CD34 and presence of mast cells in eight oral neurofibromas, and a review of 127 cases of the literature. J. Bras. Patol. Med. Lab 2013; 49(5):347-354. https://doi.org/10. 1590/S1676-24442013000500008.
9. Ji Young P, Hoon P, Nam Jo P, June Sik P, Hyun-Jung S, Sang Sook L. Use of Calretinin ,CD56 and CD34 for differential diagnosis of Schwannoma and Neurofibroma. Korean J Pathol 2011; 45(1):30. doi:10.4132/KoreanJPathol.2011.45. 1 .30.
10. Fletcher DMC. Tumours of the peripheral nervous system. In: Houston M, DeFrancesco K. (eds) Fletcher DMC. Diagnostic histopathology of tumours. 5th ed. Philadelphia: Elsevier; 2021. p2172-2191
11. Weiss WS, Goldblum RJ. Benign and Malignant tumours of peripheral nerve. In: Enzinger and Weiss’s Soft Tissue Tumours. 7th ed. Philadelphia: Elsevier Saunders; 2020. p 885-985.
12. Guha D, Davidson B, Nadi M, Alotaibi NM, Fehlings MG, Gentili F, et al. Management of peripheral nerve sheath tumours: 17 years of experience at Toronto Western Hospital. J Neurosurg 2018; 128(4):1226-1234. doi:10.3171/2017.1.JNS162292.
13. Kadivar M, Aram F. Assessment of Ki 67 in breast cancer: a comparison between the Eye -10 method, stepwise counting strategy, and international system of Ki 67 evaluation. Iran J Pathol 2020; 15(1):13-18. doi: 10.30699/IJP.2019.102290.2017
14. Gabhane SK, Kotwal MN, Bobhate SK. Morphological spectrum of peripheral nerve sheath tumours: a series of 126 cases. Indian J Pathol Microbiol 2009; 52(1):29-33. doi:10.4103/0377-4929.44958.
15. Chikkannaiah P, Boovalli MM, Nathiyal V, Venkataramappa S. Morphological spectrum of peripheral nerve sheath tumours: an insight into World Health Organization 2013 classification. J Neurosci Rural Pract 2016; 7(3):346-354. doi:10.4103/0976-3147.182768.
16. Fine SW, McClain SA, Li M. Immunohistochemical staining for calretinin is useful for differentiating schwannomas from neurofibromas. Am J Clin Pathol 2004; 122(4):552-559.doi:10.1309/AGBG-TBRJ-4W0B-C7LN.
17. Awf Sh M, Bashar H, Omar M, Ameer DH. Comparative clinicopathological and immunohistochemical study of oral schwannomas and neurofibromas. J Res Med Dent Sci 2021; 9(5):27-34.
18. Khalifa MA, Montgomery EA, Ismiil N, Azumi N. What are the CD34+ cells in benign peripheral nerve sheath tumours? Double immunostaining study of CD34 and S-100 proteins. Am J Clin Pathol 2000; 114:123-126.doi: 10.1309/C7N9-J2AU-5TB9-5FRL .
19. Ademiluyi SA, Sowemimo GO, Oyeneyin JO. Surgical experience in the management of multiple neurofibromatosis in Nigerians. West Afr J Med. 1989; 8(1):59-65.
20. Onunu AN, Lawal NA. Neurofibromatosis 1: a clinical study in the Nigerian African. Ann. Biomed. Sci. 2002; 1(2):118-123. doi: 10.4314/abs.v1i2.40631
21. Azeke AT, Imasogie DE. A review of histologically diagnosed neurofibroma: an institution based study spanning a decade. SSRG-IJMS. 2018; 5(6):2-4. http://www.internationaljournalssrg.org ISSN: 2393-9117.